Mr. Keita Shimizu, Science Class III, The University of Tokyo, 1st year As I was rocked on the Yamanote Line as it traveled through Tokyo late at night, I was left with two conflicting emotions. One was a sense elation. The other was a sense self-reflection. I had the opportunity to participate as a student staff member in the 19th Symposium of the Council for Promoting Medical Reform from the Field on November 16th and 17th last year. I entered the University of Tokyo in Apr

Masahiro Kami, M.D., Ph.D. President, Medical Governance Research Institute, Tokyo, Japan Keywords: #Ministry of Health, Labour and Welfare, #National Medical Licensing Examination, #Doctor Shortage, #Aesthetic Clinics, #Doctor Maldistribution, #Cosmetic Surgery As the maldistribution of doctors exacerbates shortages in rural areas and certain specialties, the government has proposed measures to regulate the outflow of doctors to aesthetic clinics, which has been cited as o

Tetsuya Tanimoto, MD. Chairman of Accessible Railway Medical Services Tetsuikai Medical Corporation. Director of Navitas Clinic Kawasaki Monet: A Name You Know, Even If You Don’t Know Why Oscar-Claude Monet (1840–1926) is one of those names you’ve probably heard, even if your knowledge of art is limited to doodles in the margins of a notebook. Maybe you remember him as the guy who painted all those water lilies. Maybe you think of Impressionism, even if you’re not entirely su

Kana Yamamoto, M.D., Ph.D Physician, Medical Governance Research Institute "A Little Iken(Medical Opinion) Notebook" is a column in...

东京大学 第一学期 理科 3 班，第一年 清水圭太 中国没有“保险”概念的情况 说白了，中国的社会保障制度落后于日本。在日本，如果你生病或感觉不适，通常可以以合理的费用接受医疗。 这得益于作为国家机构而建立的社会保障制度，该制度适用于日本的任何地方。 但在中国，此类社会保障制度的发展却比较滞后。尽管中国的目标是实现全民健康保险制度，但城市学生和农村所有人均可选择购买公共医疗保险。 特别是在农村地区，“保险”这个概念并不为民众所熟悉，花钱预防疾病或受伤的想法似乎很难理解。 然而，由于中国的特殊国情，患病人数不断增加。 访问中国评估大学现状 今年3月9日，我有幸访问了中国复旦大学公共卫生学院，并与姜庆五教授会面。 我随姜教授会见了王和兴教授和王继伟副教授，并在与他们指导的研究生交流时，听取了他们对中国面临的各种公共卫生挑战的看法。 因为我考虑今后当一名医生，所以想认识一位中国的医生，经医疗管理所上昌广教授介绍，我认识了姜教授。 目前东京大学有大量中国留学生，研究生的数量远远多于本科生。他们一般都很优秀。有“在中国剧烈竞争的入学考试中脱颖而出的

Masahiro Kami, M.D., Ph.D. President, Medical Governance Research Institute, Tokyo, Japan The COVID-19 vaccine KOSTAIVE, developed by Meiji Seika Pharma, a subsidiary of Meiji Holdings (Meiji HD), is drawing public attention. Social media is overflowing with rumors such as false claims that "shedding from vaccinated individuals can infect others around them." Shedding refers to the idea that after KOSTAIVE proliferates in the recipient’s body, some of it is released into the

Masaharu Tsubokura, M.D., Ph.D. Chief Professor, Department of Radiation Health Management, School of Medicine, Fukushima Medical...

医疗管理研究所理事长 上 昌广 ● 63％的在线诊疗用户是儿科患者。 在新冠疫情中，医疗将如何改变呢？我关注的是在线诊疗的普及，特别是儿科似乎很适合。 2023年1月，美国斯坦福大学的医生们在《家庭医学会刊》上报告说，对12-18岁患者的诊疗有43％是通过在线问诊完成的。...

Tetsuya Tanimoto, MD. Chairman of Accessible Railway Medical Services Tetsuikai Medical Corporation. Director of Navitas Clinic Kawasaki...

Masahiro Kami, M.D., Ph.D. President, Medical Governance Research Institute, Tokyo, Japan From May 25 to 27, the traditional festival of...

Akihiko Ozaki, M.D., Ph.D. Physician at the Medical Governance Research Institute Is there any influence from pharmaceutical companies on the medicines doctors prescribe? On August 10th, 2024, medical students and young doctors tackled this sensitive issue head-on at a symposium held at the 56th Japanese Society of Medical Education Conference held at Teikyo University. "56.9% of doctors meet with pharmaceutical companies at least once a week." The results of our questionna

In a recent discussion, Dr. Satoshi Umemura, a member of the House of Representatives and an internal medicine physician, engaged with...

谷本哲也博士 围绕52岁前媒体人物中居正广的争议，已在日本娱乐及广播行业引发重动荡。中居正广曾是男子偶像组合SMAP的成员，他被指控在2023年6月的一次晚餐中，对一名20多岁的富士电视台女员工实施性侵犯。据报道，他与该女子达成庭外和解，支付了9000万日元（约合人民币42...

Left: Tetsuya Tanimoto Tetsuya Tanimoto, MD. Chairman of Accessible Railway Medical Services Tetsuikai Medical Corporation. Director of...

By: Tetsuya Tanimoto, MD Chairman of Accessible Railway Medical Services Tetsuikai Medical Corporation Director of Navitas Clinic Kawasaki In the ever-evolving world of metabolic health management, we stand at a peculiar, almost mystical crossroads. On one side, a line-up of cutting-edge pharmaceuticals, the stars of which are GLP-1 receptor agonists, have appeared, almost from thin air. These drugs—sleek, precise, and modern—promise a life free from constant hunger and the w